Perspectives on EGFR-mutant and wildtype NSCLC Tailoring treatment advances in late-stage disease - touchONCOLOGY

touchCLINICAL PERSPECTIVES for touchONCOLOGY

Join Dr Helena Yu, course director, as she discusses the unmet needs and research opportunities in metastatic EGFR-mutant and wildtype NSCLC. By exploring key clinical trial data alongside real-world patient cases, healthcare providers will gain valuable insights into how to effectively implement these findings in clinical practice. In addition, the clinical experts highlight the critical role of biomarker testing in NSCLC for personalizing treatment plans and discuss the importance of patient support in navigating the NSCLC treatment journey.

Course director

Dr Helena Yu, Memorial Sloan Kettering Cancer Center New York, NY, USA

The clinical experts

Dr Aaron Lisberg, University of California Los Angeles (UCLA), Los Angeles, CA, USA

Dr Antonio Passaro, European Institute of Oncology, Milan, Italy

Dr Sara Pilotto, University of Verona, Verona, Italy

Ms Jackie Fenemore, Christie NHS Foundation Trust, Manchester, UK

Prof. Egbert Smit, Leiden University Medical Center, Leiden, The Netherlands and Netherlands Cancer Institute, Amsterdam, The Netherlands

Modules

Module 1: EGFR-mutant NSCLC: Navigating the horizon in EGFR-mutant NSCLC (timestamp: 0:00 - 32:33)

Module 2: EGFR-wildtype NSCLC: Advances in the treatment landscape (timestamp: 32:34 - 01:06:10)

Module 3: Bringing it together (timestamp: 01:06:10 - 01:43:40)

 

This touchPODCAST is for HCPs only.

This activity is funded by an educational grant from AstraZeneca Ltd. 

This medical education is jointly provided by USF Health and touchIME. touchIME is an EBAC® accredited provider.

 

For further information visit our website:  
https://touchoncologyime.org/egfr-and-wildtype-late-stage-nsclc-management/